2016
DOI: 10.1507/endocrj.ej15-0435
|View full text |Cite
|
Sign up to set email alerts
|

Association of polymorphisms in the <i>ICOS</i> and <i>ICOSL</i> genes with the pathogenesis of autoimmune thyroid diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 39 publications
0
4
0
Order By: Relevance
“…Single cells from spleens and draining lymph nodes of WT skin-grafted Dsg3 -/mice and from spleens of Rag1 -/mice given the various cell populations from WT skin-grafted Dsg3 -/mice were surface-stained at 48C for 20 minutes with the following antibodies: anti-CD3e-BV510 (145-2C11), anti-CD3e-PerCP-Cy5.5 (145-2C11), anti-CD4-APC-Cy7 (GK1.5), anti-CD4-PE-Cy7 (GK1.5), biotin anti-CXCR5 (2G8), anti-CD44-APC-R700 (IM7), anti-CD62L-BB515 (MEL-14), anti-CD19-PE-CF594 (1D3), anti-CD25-BV786 (PC61) anti-B220-BV650 (RA3-6B2), anti-B220-PerCP-Cy5.5 (RA3-6B2), anti-Fas-BV421 (Jo2), anti-Fas-PE-Cy7 (Jo2), anti-GL7-PE (GL7), anti-CD138-APC (281-2), anti-NK1.1-Alexa Fluor 700 (PK136) (all from BD Biosciences); anti-PD-1-BV605 (29F.1A12), anti-PD-1-PE (29F.1A12) (both from BioLegend San Diego, Calif); anti-ICOS-PE-Cy7 (C398.4A), anti-IgD-APC-Cy7 (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26), and anti-CD3-Alexa Fluor 700 (500A2) (all from Invitrogen). For the staining of human PBMCs the following were used for surface staining at 48C for 20 minutes: anti-CD3-BV786 (SK7), anti-CD4-APC-Cy7 (RPA-T4), biotin anti-CXCR5 (RF8B2), anti-CD45RA-FITC (HI100), anti-CCR7-PE-Cy7 (3D12), anti-CD14-BV510 (M4P-9), anti-CD8-BV510 (SK1), anti-CCR6-APC-R700 (11A9) (all from BD Biosciences); anti-PD-1-BV605 (EH12.2H7) (from BioLegend); anti-CD19-BV510 (HIB19), anti-ICOS-APC (ISA-3) (both from Invitrogen); and anti-CXCR3-PE (49801; R&D Systems).…”
Section: Flow Cytometrymentioning
confidence: 99%
See 1 more Smart Citation
“…Single cells from spleens and draining lymph nodes of WT skin-grafted Dsg3 -/mice and from spleens of Rag1 -/mice given the various cell populations from WT skin-grafted Dsg3 -/mice were surface-stained at 48C for 20 minutes with the following antibodies: anti-CD3e-BV510 (145-2C11), anti-CD3e-PerCP-Cy5.5 (145-2C11), anti-CD4-APC-Cy7 (GK1.5), anti-CD4-PE-Cy7 (GK1.5), biotin anti-CXCR5 (2G8), anti-CD44-APC-R700 (IM7), anti-CD62L-BB515 (MEL-14), anti-CD19-PE-CF594 (1D3), anti-CD25-BV786 (PC61) anti-B220-BV650 (RA3-6B2), anti-B220-PerCP-Cy5.5 (RA3-6B2), anti-Fas-BV421 (Jo2), anti-Fas-PE-Cy7 (Jo2), anti-GL7-PE (GL7), anti-CD138-APC (281-2), anti-NK1.1-Alexa Fluor 700 (PK136) (all from BD Biosciences); anti-PD-1-BV605 (29F.1A12), anti-PD-1-PE (29F.1A12) (both from BioLegend San Diego, Calif); anti-ICOS-PE-Cy7 (C398.4A), anti-IgD-APC-Cy7 (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26), and anti-CD3-Alexa Fluor 700 (500A2) (all from Invitrogen). For the staining of human PBMCs the following were used for surface staining at 48C for 20 minutes: anti-CD3-BV786 (SK7), anti-CD4-APC-Cy7 (RPA-T4), biotin anti-CXCR5 (RF8B2), anti-CD45RA-FITC (HI100), anti-CCR7-PE-Cy7 (3D12), anti-CD14-BV510 (M4P-9), anti-CD8-BV510 (SK1), anti-CCR6-APC-R700 (11A9) (all from BD Biosciences); anti-PD-1-BV605 (EH12.2H7) (from BioLegend); anti-CD19-BV510 (HIB19), anti-ICOS-APC (ISA-3) (both from Invitrogen); and anti-CXCR3-PE (49801; R&D Systems).…”
Section: Flow Cytometrymentioning
confidence: 99%
“…ICOS can be expressed on all activated T cells, but is especially critical in T FH cell differentiation and maintenance, as well as the GC response. 10,11 ICOS polymorphisms have been associated with various autoimmune diseases, 12,13 and anti-ICOS blocking antibody has been used to target ICOS 1 T FH cell activation in mouse models of autoimmune disease, including systemic lupus erythematosus and lupus nephritis. 14,15 Recently, an anti-ICOS depleting antibody was shown to control systemic sclerosis by reducing ICOS 1 T FH -like cells in the skin.…”
mentioning
confidence: 99%
“…ICOSLG-ICOS interaction is implicated in multiple immune processes, such as the establishment of CD8+ tissue resident T cells in intestine ( 64 ). Altogether, these interactions point to the importance of ICOS interactions, which have been found to have relevance in multiple autoimmune diseases ( 65 67 ).…”
Section: Discussionmentioning
confidence: 89%
“…Therefore, ICOSL may be an option for the treatment of autoimmune diseases. Studies have shown that the polymorphisms of ICOSLG were associated with an increased risk of RA, autoimmune thyroid diseases, and SLE (17)(18)(19).…”
Section: Introductionmentioning
confidence: 99%